Exane BNP Paribas reinstated coverage of Essity with a Neutral rating and SEK 280 price target. The analyst says reducing exposure to tissue should drive less earnings volatility for the company.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
